Current and future approaches to the prevention and treatment of staphylococcal medical device-related infections

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 100-113

  Hogan, S ^a   Stevens, N T ^a   Humphreys, H ^a   O'Gara J P ^b   O'Neill E ^a,c  

^a BEAUMONT HOSPITAL   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c Stroke and Hypertension Unit   (Ireland)

Author keywords

Biofilm; Management; Prophylaxis; Staphylococcus

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; APOTRANSFERRIN; BINDING PROTEIN; BIOMATERIAL; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHLORHEXIDINE; CITRATE SODIUM; COLLAGEN; COLLAGEN BINDING PROTEIN; COPPER; DEOXYRIBONUCLEASE I; EDETIC ACID; EGTAZIC ACID; FIBRINOGEN; FIBRONECTIN; FIBRONECTIN BINDING PROTEIN; GENTAMICIN; LYSOSTAPHIN; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SCLEROPROTEIN; SIGMA FACTOR; SILVER; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS SUBTILIS; BACTERIOPHAGE; BACTERIUM ADHERENCE; BIOFILM; CATHETER; DEVICE INFECTION; HUMAN; IMMUNE EVASION; IMMUNIZATION; INFECTION PREVENTION; MEDICAL DEVICE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; QUORUM SENSING; REGULATOR GENE; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SURFACE PROPERTY; ANIMAL; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 84919754869     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905123900     Document Type: Article

References (175)

1. Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 2012; 272(6): 541-61.
2. Raad I. Intravascular-catheter-related infections. The Lancet 1998; 351(9106): 898.
3. Sutherland IW. The biofilm matrix-an immobilized but dynamic microbial environment. Trends Microbiol 2001; 9(5): 222-7.
4. Monroe D. Looking for chinks in the armor of bacterial biofilms. PLoS Biol 2007; 5(11): e307.
5. Beenken KE, Blevins JS, Smeltzer MS. Mutation of sarA in Staphylococcus aureus limits biofilm formation. Infect Immun 2003; 71(7): 4206-11.
6. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 2008; 4(4): e1000052.
7. Conlon KM, Humphreys H, O'Gara JP. Regulation of icaR gene expression in Staphylococcus epidermidis. FEMS Microbiol Lett 2002; 216(2): 171-7.
8. Houston P, Rowe SE, Pozzi C, Waters EM, O'Gara JP. Essential role for the major autolysin in the fibronectin-binding proteinmediated Staphylococcus aureus biofilm phenotype. Infect Immun 2011; 79(3): 1153-65.
9. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci 2011; 1241: 104-21.
10. Ryder MA. Catheter-Related Infections: It's All About Biofilm Advanced Practice Nursing eJournal 2005; 5(3).
11. Sakai H, Procop GW, Kobayashi N, et al. Simultaneous detection of Staphylococcus aureus and coagulase-negative staphylococci in positive blood cultures by real-time PCR with two fluorescence resonance energy transfer probe sets. J Clin Microbiol 2004; 42(12): 5739-44.
12. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol 2008; 322: 207-28.
13. Ghannoum MA, O'Toole GA. Microbial Biofilms2004.
14. Biswas R, Voggu L, Simon UK, et al. Activity of the major staphylococcal autolysin Atl. FEMS Microbiol Lett 2006; 259(2): 260-8.
15. Takahashi J, Komatsuzawa H, Yamada S, et al. Molecular characterization of an atl null mutant of Staphylococcus aureus. Microbiol Immunol 2002; 46(9): 601-12.
16. O'Gara JP. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett 2007; 270(2): 179-88.
17. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annual review Microbiology 1994; 48: 585-617.
18. Gross M, Cramton SE, Götz F, Peschel A. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun 2001; 69(5): 3423-6.
19. Weidenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004; 10(3): 243-5.
20. Fedtke I, Mader D, Kohler T, et al. A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity. Mol Microbiol 2007; 65(4): 1078-91.
21. Houston P, Rowe SE, Pozzi C, Waters EM, O'Gara JP. Essential role for the major utolysin in the fibronectin-binding proteinmediated Staphylococcus aureus biofilm phenotype. Infection and Immunity 2011; 79(3): 1165.
22. Knobloch JK, Bartscht K, Sabottke A, et al. Biofilm formation by Staphylococcus epidermidis depends on functional RsbU, an activator of the sigB operon: differential activation mechanisms due to ethanol and salt stress. J Bacteriol 2001; 183(8): 2624-33.
23. Rohde H, Burdelski C, Bartscht K, et al. Induction of Staphylococcus epidermidis biofilm formation via proteolytic processing of the accumulation-associated protein by staphylococcal and host proteases. Mol Microbiol 2005; 55(6): 1883-95.
24. Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 1999; 67(10): 5427-33.
25. Heilmann C, Schweitzer O, Gerke C, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol 1996; 20(5): 1083-91.
26. Gerke C, Kraft A, Süssmuth R, Schweitzer O, Götz F. Characterization of the N-acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin. J Biol Chem 1998; 273(29): 18586-93.
27. Fitzpatrick F, Humphreys H, O'Gara JP. Environmental regulation of biofilm development in methicillin-resistant and methicillinsusceptible Staphylococcus aureus clinical isolates. J Hosp Infect 2006; 62(1): 120-2.
28. Fitzpatrick F, Humphreys H, O'Gara JP. Evidence for icaADBCindependent biofilm development mechanism in methicillinresistant Staphylococcus aureus clinical isolates. J Clin Microbiol 2005; 43(4): 1973-6.
29. Keane FM, Loughman A, Valtulina V, et al. Fibrinogen and elastin bind to the same region within the A domain of fibronectin binding protein A, an MSCRAMM of Staphylococcus aureus. Mol Microbiol 2007; 63(3): 711-23.
30. O'Neill E, Pozzi C, Houston P, et al. A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol 2008; 190(11): 3835-50.
31. Jönsson K, Signäs C, Müller HP, Lindberg M. Two different genes encode fibronectin binding proteins in Staphylococcus aureus. The complete nucleotide sequence and characterization of the second gene. Eur J Biochem 1991; 202(3): 1041-8.
32. Geoghegan JA, Monk IR, O'Gara JP, Foster TJ. Subdomains N2N3 of Fibronectin Binding Protein A Mediate Staphylococcus aureus Biofilm Formation and Adherence to Fibrinogen Using Distinct Mechanisms. J Bacteriol 2013; 195(11): 2675-83.
33. Tormo MA, Knecht E, Götz F, Lasa I, Penadés JR. Bap-dependent biofilm formation by pathogenic species of Staphylococcus: evidence of horizontal gene transfer? Microbiology 2005; 151(Pt 7): 2465-75.
34. Bien J, Sokolova O, Bozko P. Characterization of Virulence Factors of Staphylococcus aureus: Novel Function of Known Virulence Factors That Are Implicated in Activation of Airway Epithelial Proinflammatory Response. J Pathog 2011; 2011: 601905.
35. Pozzi C, Waters EM, Rudkin JK, et al. Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog 2012; 8(4): e1002626.
36. Recsei P, Kreiswirth B, O'Reilly M, et al. Regulation of exoprotein gene expression in Staphylococcus sureus by agar. Molecular and general genetics 1986; 202(1): 58-61.
37. Gospodarek E, Bogiel T, Zalas-Wiecek P. Communication between microorganisms as a basis for production of virulence factors. Pol J Microbiol 2009; 58(3): 191-8.
38. Lyon GJ, Novick RP. Peptide signaling in Staphylococcus aureus and other Gram-positive bacteria. Peptides 2004; 25(9): 1389-403.
39. Novick RP, Ross HF, Projan SJ, et al. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J 1993; 12(10): 3967-75.
40. Boles BR, Horswill AR. Staphylococcal biofilm disassembly. Trends Microbiol 2011; 19(9): 449-55.
41. Vuong C, Saenz HL, Götz F, Otto M. Impact of the agr quorumsensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis 2000; 182(6): 1688-93.
42. O'Neill E, Pozzi C, Houston P, et al. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J Clin Microbiol 2007; 45(5): 1379-88.
43. Valle J, Toledo-Arana A, Berasain C, et al. SarA and not sigmaB is essential for biofilm development by Staphylococcus aureus. Mol Microbiol 2003; 48(4): 1075-87.
44. Dunman PM, Murphy E, Haney S, et al. Transcription profilingbased identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001; 183(24): 7341-53.
45. Chan PF, Foster SJ, Ingham E, Clements MO. The Staphylococcus aureus alternative sigma factor sigmaB controls the environmental stress response but not starvation survival or pathogenicity in a mouse abscess model. J Bacteriol 1998; 180(23): 6082-9.
46. Gross CA, Chan C, Dombroski A, et al. The functional and regulatory roles of sigma factors in transcription. Cold Spring Harb Symp Quant Biol 1998; 63: 141-55.
47. Klotchko A, Wallace MR, Licitra C, Sieger B. Staphylococcus lugdunensis: an emerging pathogen. South Med J 2011; 104(7): 509-14.
48. Bischoff M, Dunman P, Kormanec J, et al. Microarray-based analysis of the Staphylococcus aureus sigmaB regulon. J Bacteriol 2004; 186(13): 4085-99.
49. Pratt RJ, Pellowe CM, Wilson JA, et al. epic2: National evidencebased guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007; 65 Suppl 1: S1-64.
50. Aboelela SW, Stone PW, Larson EL. Effectiveness of bundled behavioural interventions to control healthcare-associated infections: a systematic review of the literature. J Hosp Infect 2007; 66(2): 101-8.
51. Flodgren G, Conterno LO, Mayhew A, et al. Interventions to improve professional adherence to guidelines for prevention of device-related infections. Cochrane Database Syst Rev 2013; 3: CD006559.
52. Timsit JF, Schwebel C, Bouadma L, et al. Chlorhexidineimpregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009; 301(12): 1231-41.
53. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methlene blue/parabens). Nephrol Dial Transplant 2009; 24: 1945.
54. Heilmann C, Götz F. Cell-Cell Communication and Biofilm Formation in Gram-Positive Bacteria, in Bacterial Signaling. In: Krämer R, Jung K, editors. Bacterial Signaling. Germany: Wiley-VCH Verlag GmbH & Co; 2010.
55. François P, Vaudaux P, Lew PD. Role of plasma and extracellular matrix proteins in the physiopathology of foreign body infections. Ann Vasc Surg 1998; 12(1): 34-40.
56. Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998 Dec; 6(12): 484-8.
57. O'Toole GA, Stewart PS. Biofilms strike back. Nat Biotechnol 2005; 23(11): 1378-9.
58. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358(9276): 135-8.
59. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66(2): 86-92.
60. Fernández-Hidalgo N, Gavaldà J, Almirante B, et al. Evaluation of linezolid, vancomycin, gentamicin and ciprofloxacin in a rabbit model of antibiotic-lock technique for Staphylococcus aureus catheter-related infection. J Antimicrob Chemother 2010; 65(3): 525-30.
61. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycinresistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51(1): 231-8.
62. Del Pozo JL, Rodil R, Aguinaga A, et al. Daptomycin lock therapy for grampositive long-term catheter-related bloodstream infections. Int J Clin Pract 2012; 66(3): 305-8.
63. Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2002; 46(3): 900-3.
64. Gattringer KB, Suchomel M, Eder M, et al. Time-dependent effects of rifampicin on staphylococcal biofilms. Int J Artif Organs 2010; 33(9): 621-6.
65. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51(5): 1656-60.
66. Svensson E, Hanberger H, Nilsson M, Nilsson LE. Factors affecting development of rifampicin resistance in biofilmproducing Staphylococcus epidermidis. J Antimicrob Chemother 1997; 39(6): 817-20.
67. Cicalini S, Palmieri F, Petrosillo N. New technologies for prevention of intravascular catheter-related infections. Critical Care 2004; 8(3): 162.
68. Yahav D, Rozen-Zvi B, Gafter-Gvili A, et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008; 47(1): 83-93.
69. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1): 1-45.
70. Shah CB, Mittelman MW, Costerton JW, et al. Antimicrobial Activity of a Novel Catheter Lock Solution. Antimicrobial Agenta and Chemotherapy 2002; 46(6).
71. Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73(8): 4596-606.
72. Balestrino D, Souweine B, Charbonnel N, et al. Eradication of microorganisms embedded in biofilm by an ethanol-based catheter lock solution. Nephrol Dial Transplant 2009; 24(10): 3204-9.
73. Wolf J, Shenep JL, Clifford V, Curtis N, Flynn PM. Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer 2012.
74. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17(12): 2189-95.
75. Winnett G, Nolan J, Miller M, Ashman N. Trisodium citrate 46. 7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant 2008; 23(11): 3592-8.
76. Bosma JW, Siegert CE, Peerbooms PG, Weijmer MC. Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 2010; 25(4): 1213-7.
77. Maki DG, Ash SR, Winger RK, Lavin P, Investigators AT. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 2011; 39(4): 613-20.
78. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 2009; 53(6): 1034-41.
79. Dagley S, Dawes EA, Morrison GA. Inhibition of growth of Aerobacter aerogenes; the mode of action of phenols, alcohols, acetone, and ethyl acetate. J Bacteriol 1950; 60(4): 369-79.
80. Sanders J, Pithie A, Ganly P, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 2008; 62(4): 809-15.
81. Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. JPEN J Parenter Enteral Nutr 2011; 35(1): 67-73.
82. Cober MP, Johnson CE. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health Syst Pharm 2007; 64(23): 2480-2.
83. Macias JH, Arreguin V, Munoz JM, et al. Chlorhexidine is a better antiseptic than povidone iodine and sodium hypochlorite because of its substantive effect. Am J Infect Control 2013.
84. Franklin TJ, Snow GA. Biochemistry and Molecular Biology of Antimicrobial Drug Action. 6th ed. New York: Springer; 2005.
85. Harro C, Betts R, Orenstein W, et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol 2010; 17(12): 1868-74.
86. McKenney D, Pouliot KL, Wang Y, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284(5419): 1523-7.
87. Maira-Litrán T, Kropec A, Abeygunawardana C, et al. Immunochemical properties of the staphylococcal poly-Nacetylglucosamine surface polysaccharide. Infect Immun 2002; 70(8): 4433-40.
88. Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. Trends Microbiol 1999; 7(4): 140-1.
89. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184(12): 1572-80.
90. Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006; 74(4): 2145-53.
91. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74(4): 2215-23.
92. Zhou H, Xiong ZY, Li HP, Zheng YL, Jiang YQ. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 2006; 24(22): 4830-7.
93. Brady RA, O'May GA, Leid JG, et al. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun 2011; 79(4): 1797-803.
94. Shahrooei M, Hira V, Khodaparast L, et al. Vaccination with SesC decreases Staphylococcus epidermidis biofilm formation. Infect Immun 2012; 80(10): 3660-8.
95. Abu el-Asrar AM, Shibl AM, Tabbara KF, al-Kharashi SA. Heparin and heparin-surface-modification reduce Staphylococcus epidermidis adhesion to intraocular lenses. Int Ophthalmol 1997; 21(2): 71-4.
96. Speziale P, Visai L, Rindi S, et al. Prevention and treatment of Staphylococcus biofilms. Curr Med Chem 2008; 15(30): 3185-95.
97. Hanna H, Bahna P, Reitzel R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother 2006; 50(10): 3283-8.
98. Hansen LK, Berg K, Johnson D, Sanders M, Citron M. Efficacy of local rifampin/minocycline delivery (AIGIS(RX)®) to eliminate biofilm formation on implanted pacing devices in a rabbit model. Int J Artif Organs 2010; 33(9): 627-35.
99. Zhao L, Wang H, Huo K, et al. Antibacterial nano-structured titania coating incorporated with silver nanoparticles. Biomaterials 2011; 32(24): 5706-16.
100. Kalishwaralal K, BarathManiKanth S, Pandian SR, Deepak V, Gurunathan S. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surf B Biointerfaces 2010; 79(2): 340-4.
101. Fiedler J, Kolitsch A, Kleffner B, et al. Copper and silver ion implantation of aluminium oxide-blasted titanium surfaces: proliferative response of osteoblasts and antibacterial effects. Int J Artif Organs 2011; 34(9): 882-8.
102. Kadry AA, Fouda SI, Shibl AM, Abu El-Asrar AA. Impact of slime dispersants and anti-adhesives on in vitro biofilm formation of Staphylococcus epidermidis on intraocular lenses and on antibiotic activities. J Antimicrob Chemother 2009; 63(3): 480-4.
103. Pavesio A, Renier D, Cassinelli C, Morra M. Anti-adhesive surfaces through hyaluronan coatings. Med Device Technol 1997; 8(7): 20-1, 4-7.
104. Pirnazar P, Wolinsky L, Nachnani S, et al. Bacteriostatic effects of hyaluronic acid. J Periodontol 1999; 70(4): 370-4.
105. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003; 47(11): 3407-14.
106. Dajcs JJ, Hume EB, Moreau JM, et al. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 2000; 41(6): 1432-7.
107. Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 2009; 64(1): 94-100.
108. Aguinaga A, Francés ML, Del Pozo JL, et al. Lysostaphin and clarithromycin: a promising combination for the eradication of Staphylococcus aureus biofilms. Int J Antimicrob Agents 2011; 37(6): 585-7.
109. Donelli G, Francolini I, Romoli D, et al. Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Antimicrob Agents Chemother 2007 Aug; 51(8): 2733-40.
110. Kaplan JB. Therapeutic potential of biofilm-dispersing enzymes. Int J Artif Organs 2009 Sep; 32(9): 545-54.
111. Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N. Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2004 Jul; 48(7): 2633-6.
112. Eckhart L, Fischer H, Barken KB, Tolker-Nielsen T, Tschachler E. DNase1L2 suppresses biofilm formation by Pseudomonas aeruginosa and Staphylococcus aureus. Br J Dermatol 2007; 156(6): 1342-5.
113. Qin Z, Ou Y, Yang L, et al. Role of autolysin-mediated DNA release in biofilm formation of Staphylococcus epidermidis. Microbiology 2007 Jul; 153(Pt 7): 2083-92.
114. Seidl K, Goerke C, Wolz C, et al. Staphylococcus aureus CcpA affects biofilm formation. Infect Immun 2008 May; 76(5): 2044-50.
115. McGavin MJ, Zahradka C, Rice K, Scott JE. Modification of the Staphylococcus aureus fibronectin binding phenotype by V8 protease. Infect Immun 1997 Jul; 65(7): 2621-8.
116. Houmard J, Drapeau GR. Staphylococcal protease: a proteolytic enzyme specific for glutamoyl bonds. Proc Natl Acad Sci USA 1972 Dec; 69(12): 3506-9.
117. Chaignon P, Sadovskaya I, Ragunah C, et al. Susceptibility of staphylococcal biofilms to enzymatic treatments depends on their chemical composition. Appl Microbiol Biotechnol 2007 May; 75(1): 125-32.
118. Kumar Shukla S, Rao TS. Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K. J Antibiot (Tokyo) 2013 Feb; 66(2): 55-60.
119. Park JH, Lee JH, Cho MH, Herzberg M, Lee J. Acceleration of protease effect on Staphylococcus aureus biofilm dispersal. FEMS Microbiol Lett 2012 Oct; 335(1): 31-8.
120. Lubarsky HV, Gerbersdorf SU, Hubas C, et al. Impairment of the bacterial biofilm stability by triclosan. PLoS One 2012; 7(4): e31183.
121. Jori G. Photodynamic therapy of microbial infections: state of the art and perspectives. J Environ Pathol Toxicol Oncol 2006; 25(1-2): 505-19.
122. Sharma M, Visai L, Bragheri F, et al. Toluidine blue-mediated photodynamic effects on staphylococcal biofilms. Antimicrob Agents Chemother 2008 Jan; 52(1): 299-305.
123. Park JH, Ahn MY, Kim YC, et al. In vitro and in vivo antimicrobial effect of photodynamic therapy using a highly pure chlorin e6 against Staphylococcus aureus Xen29. Biol Pharm Bull 2012; 35(4): 509-14.
124. Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs 2011 Sep; 34(9): 727-36.
125. Drago L, De Vecchi E, Mattina R, Romanò CL. Activity of Nacetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013 Jan; 36(1): 39-46.
126. Baffone W, Sorgente G, Campana R, et al. Comparative effect of chlorhexidine and some mouthrinses on bacterial biofilm formation on titanium surface. Curr Microbiol 2011 Feb; 62(2): 445-51.
127. Sulemankhil I, Ganopolsky JG, Dieni CA, et al. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob Agents Chemother 2012 Dec; 56(12): 6095-103.
128. Junka A, Bartoszewicz M, Smutnicka D, Secewicz A, Szymczyk P. Efficacy of antiseptics containing povidone-iodine, octenidine dihydrochloride and ethacridine lactate against biofilm formed by Pseudomonas aeruginosa and Staphylococcus aureus measured with the novel biofilm-oriented antiseptics test. Int Wound J 2013 Feb.
129. Olson KM, Starks CM, Williams RB, et al. Novel pentadecenyl tetrazole enhances susceptibility of methicillin-resistant Staphylococcus aureus biofilms to gentamicin. Antimicrob Agents Chemother 2011 Aug; 55(8): 3691-5.
130. Ardehali R, Shi L, Janatova J, Mohammad SF, Burns GL. The effect of apo-transferrin on bacterial adhesion to biomaterials. Artif Organs 2002; 26(6): 512-20.
131. Lyte M, Freestone PP, Neal CP, et al. Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. Lancet 2003; 361(9352): 130-5.
132. Johnson M, Cockayne A, Williams PH, Morrissey JA. Ironresponsive regulation of biofilm formation in staphylococcus aureus involves fur-dependent and fur-independent mechanisms. J Bacteriol 2005; 187(23): 8211-5.
133. Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 2009; 43(2): 210-9.
134. Robertson EJ, Wolf JM, Casadevall A. EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans. Appl Environ Microbiol 2012; 78(22): 7977-84.
135. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broadspectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother 2012; 56(12): 6310-8.
136. Abraham NM, Lamlertthon S, Fowler VG, Jefferson KK. Chelating agents exert distinct effects on biofilm formation in Staphylococcus aureus depending on strain background: role for clumping factor B. J Med Microbiol 2012; 61(Pt 8): 1062-70.
137. Lin MH, Shu JC, Huang HY, Cheng YC. Involvement of iron in biofilm formation by Staphylococcus aureus. PLoS One 2012; 7(3): e34388.
138. Lin MH, Chang FR, Hua MY, Wu YC, Liu ST. Inhibitory effects of 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucopyranose on biofilm formation by Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55(3): 1021-7.
139. Beenken KE, Mrak LN, Griffin LM, et al. Epistatic relationships between sarA and agr in Staphylococcus aureus biofilm formation. PLoS One 2010; 5(5): e10790.
140. Vuong C, Gerke C, Somerville GA, Fischer ER, Otto M. Quorumsensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis 2003; 188(5): 706-18.
141. Williams P. Quorum sensing, communication and cross-kingdom signalling in the bacterial world. Microbiology 2007; 153(Pt 12): 3923-38.
142. Mehlin C, Headley CM, Klebanoff SJ. An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J Exp Med 1999; 189(6): 907-18.
143. Periasamy S, Chatterjee SS, Cheung GY, Otto M. Phenol-soluble modulins in staphylococci: What are they originally for? Commun Integr Biol 2012; 5(3): 275-7.
144. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13(12): 1510-4.
145. Wang R, Khan BA, Cheung GY, et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J Clin Invest 2011; 121(1): 238-48.
146. Walencka E, Wieckowska-Szakiel M, Rozalska S, Sadowska B, Rozalska B. A surface-active agent from Saccharomyces cerevisiae influences staphylococcal adhesion and biofilm development. Z Naturforsch C 2007 2007; 62(5-6): 433-8.
147. Davies DG, Marques CN. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol 2009; 191(5): 1393-403.
148. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol 2010; 85(6): 1629-42.
149. Jennings JA, Courtney HS, Haggard WO. Cis-2-decenoic acid inhibits S. aureus growth and biofilm in vitro: a pilot study. Clin Orthop Relat Res 2012; 470(10): 2663-70.
150. Stenz L, François P, Fischer A, et al. Impact of oleic acid (cis-9-octadecenoic acid) on bacterial viability and biofilm production in Staphylococcus aureus. FEMS Microbiol Lett 2008; 287(2): 149-55.
151. Richards JJ, Ballard TE, Melander C. Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues. Org Biomol Chem 2008; 6(8): 1356-63.
152. Reyes S, Huigens RW, Su Z, Simon ML, Melander C. Synthesis and biological activity of 2-aminoimidazole triazoles accessed by Suzuki-Miyaura cross-coupling. Org Biomol Chem 2011; 9(8): 3041-9.
153. Rogers SA, Whitehead DC, Mullikin T, Melander C. Synthesis and bacterial biofilm inhibition studies of ethyl N-(2-phenethyl) carbamate derivatives. Org Biomol Chem 2010; 8(17): 3857-9.
154. Yeagley AA, Su Z, McCullough KD, Worthington RJ, Melander C. N-substituted 2-aminoimidazole inhibitors of MRSA biofilm formation accessed through direct 1, 3-bis(tertbutoxycarbonyl) guanidine cyclization. Org Biomol Chem 2013; 11(1): 130-7.
155. Kubica M, Guzik K, Koziel J, et al. A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS One 2008; 3(1): e1409.
156. Oh KB, Kim SH, Lee J, et al. Discovery of diarylacrylonitriles as a novel series of small molecule sortase A inhibitors. J Med Chem 2004; 47(10): 2418-21.
157. Oh KB, Nam KW, Ahn H, et al. Therapeutic effect of (Z)-3-(2, 5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) against Staphylococcus aureus infection in a murine model. Biochem Biophys Res Commun 2010; 396(2): 440-4.
158. Maresso AW, Wu R, Kern JW, et al. Activation of inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 2007; 282(32): 23129-39.
159. Suree N, Yi SW, Thieu W, et al. Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem 2009; 17(20): 7174-85.
160. Frankel BA, Bentley M, Kruger RG, McCafferty DG. Vinyl sulfones: inhibitors of SrtA, a transpeptidase required for cell wall protein anchoring and virulence in Staphylococcus aureus. J Am Chem Soc 2004; 126(11): 3404-5.
161. Houry A, Gohar M, Deschamps J, et al. Bacterial swimmers that infiltrate and take over the biofilm matrix. Proc Natl Acad Sci USA 2012; 109(32): 13088-93.
162. Boles BR, Horswill AR. Swimming cells promote a dynamic environment within biofilms. Proc Natl Acad Sci USA 2012; 109(32): 12848-9.
163. Yilmaz C, Colak M, Yilmaz BC, et al. Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am 2013; 95(2): 117-25.
164. Sulakvelidze A, Morris JG. Bacteriophages as therapeutic agents. Ann Med 2001; 33(8): 507-9.
165. Seth AK, Geringer MR, Nguyen KT, et al. Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care. Plast Reconstr Surg 2013; 131(2): 225-34.
166. Fitzgerald-Hughes D, Devocelle M, Humphreys H. Beyond conventional antibiotics for the future treatment of methicillinresistant Staphylococcus aureus infections: two novel alternatives. FEMS Immunol Med Microbiol 2012.
167. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3(3): 238-50.
168. Hell E, Giske CG, Nelson A, Römling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol 2010; 50(2): 211-5.
169. Dean SN, Bishop BM, van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol 2011; 11: 114.
170. Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2012; 56(12): 6366-71.
171. Thankappan B, Jeyarajan S, Hiroaki S, et al. Antimicrobial and Antibiofilm Activity of Designed and Synthesized Antimicrobial Peptide, KABT-AMP. Appl Biochem Biotechnol 2013.
172. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as antiinfective drugs. Curr Eye Res 2005; 30(7): 505-15.
173. Kolar SL, Antonio Ibarra J, Rivera FE, et al. Extracellular proteases are key mediators of Staphylococcus aureus virulence via the global modulation of virulence-determinant stability. Microbiologyopen 2013; 2(1): 18-34.
174. Smyth ET, McIlvenny G, Enstone JE, et al. Four country healthcare associated infection prevalence survey 2006: overview of the results. J Hosp Infect 2008; 69(3): 230-48.
175. Vergara-Irigaray M, Valle J, Merino N, et al. Relevant role of fibronectin-binding proteins in Staphylococcus aureus biofilmassociated foreign-body infections. Infect Immun 2009; 77(9): 3978-91.